Tests sodium propionate in teens with kidney failure on dialysis
Compares a propionic acid food supplement with placebo in children with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Impact of Propionic Acid on Regulatory T Cell Function in Children With CKD
Key facts
- Where
- Berlin, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 20 years old?
Source: NCT05858437, who can take part
Where in Germany
- Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin BerlinBerlin, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Charite University, Berlin, Germany
- Trial code
- NCT05858437
- Record updated
- 4 November 2026
- Original description
Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.Read full original descriptionShow less
Impact of Propionic Acid on Regulatory T Cell Function in Children With Chronic Kidney Disease
Pro-Kids is a multi-center, double-blind, randomized and placebo-controlled intervention study in children with chronic kidney disease. The investigators address the effect of a dietary food supplementation of propionic acid on the immune system and the function of the intestinal barrier in CKD patients treated with hemodialysis.
Inclusion: Body weight: > 30kg; CKD G5 treated with hemodialysis; Continuous hemodialysis treatment for > 3 months; Clinical stable condition; Manifestation of CKD within childhood (<18 years).
Exclusion: Immunosuppressive therapy within the last 12 weeks before the start of the study; Pre-/pro- or postbiotic or antibiotic therapy within the last 4 weeks before the start of the study; Planned or unplanned hospitalization within in last 4 weeks before the start of the study or during study; alcohol- or drug abuse; Disease or dysfunctions, which disqualifies the patient; Acute infections; Malignant diseases; chronic gastrointestinal or hepatic diseases (for example chronic inflammatory bowel disease; Incapacity of contract or any other circumstances, which prohibit the patient or his legal guardians from understanding setup, meaning and entity of the study; Pregnancy; parallel participation on other interventional trials.